Clinical Trial Update: Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating toripalimab combined with anlotinib in unresectable locally advanced or metastatic acral malignant melanoma is ongoing with unknown sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Malignant Melanoma

Drugs mentioned

• Anlotinib (anlotinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Locally Advanced or Metastatic Acral Malignant Melanoma | Phase 2 | Status: UNKNOWN